{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:38:29Z","timestamp":1789763909916,"version":"4.0.1"},"reference-count":77,"publisher":"Xia & He Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,28]]},"DOI":"10.14218\/jcth.2020.00027","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T22:58:34Z","timestamp":1595285914000},"page":"1-7","source":"Crossref","is-referenced-by-count":34,"title":["Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications"],"prefix":"10.14218","volume":"8","author":[{"given":"Tomislav","family":"Kizivat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Maric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunja","family":"Mudri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines Bilic","family":"Curcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Primorac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Smolic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2020,7,21]]},"reference":[{"key":"key20200720225829_b1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jhep.2016.06.010","article-title":"Destined to develop NAFLD? The predictors of fatty liver from birth to adulthood","volume":"65","author":"Valenti","year":"2016","journal-title":"J Hepatol"},{"key":"key20200720225829_b2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20200720225829_b3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.dld.2017.01.147","article-title":"AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions","volume":"49","author":"Italian Association for the Study of the Liver (AISF)","year":"2017","journal-title":"Dig Liver Dis"},{"key":"key20200720225829_b4","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"key20200720225829_b5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dld.2014.09.020","article-title":"Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome","volume":"47","author":"Lonardo","year":"2015","journal-title":"Dig Liver Dis"},{"key":"key20200720225829_b6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000485998","article-title":"The metabolic syndrome in central hypogonadotrophic hypogonadism","volume":"49","author":"Dwyer","year":"2018","journal-title":"Front Horm Res"},{"key":"key20200720225829_b7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000485996","article-title":"Metabolic syndrome in thyroid disease","volume":"49","author":"Iwen","year":"2018","journal-title":"Front Horm Res"},{"key":"key20200720225829_b8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000485995","article-title":"Metabolic syndrome in polycystic ovary syndrome","volume":"49","author":"Pasquali","year":"2018","journal-title":"Front Horm Res"},{"key":"key20200720225829_b9","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.3390\/ijms20112841","article-title":"NAFLD in some common endocrine diseases: Prevalence, pathophysiology, and principles of diagnosis and management","volume":"20","author":"Lonardo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key20200720225829_b10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.dld.2018.12.014","article-title":"Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?","volume":"51","author":"Lonardo","year":"2019","journal-title":"Dig Liver Dis"},{"key":"key20200720225829_b11","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s10620-019-05687-3","article-title":"Low free triiodothyronine is associated with advanced fibrosis in patients at high risk for nonalcoholic steatohepatitis","volume":"64","author":"Manka","year":"2019","journal-title":"Dig Dis Sci"},{"key":"key20200720225829_b12","first-page":"261","article-title":"Subclinical hypothyroidism in patients with non-alcoholic fatty liver disease at the background of carbohydrate metabolism disorders","volume":"71","author":"Feisa","year":"2018","journal-title":"Wiad Lek"},{"key":"key20200720225829_b13","doi-asserted-by":"crossref","first-page":"15145","DOI":"10.1038\/s41598-018-32245-0","article-title":"Male-specific association between subclinical hypothyroidism and the risk of non-alcoholic fatty liver disease estimated by hepatic steatosis index: Korea National Health and Nutrition Examination Survey 2013 to 2015","volume":"8","author":"Lee","year":"2018","journal-title":"Sci Rep"},{"key":"key20200720225829_b14","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(17)30703-1","article-title":"Hypothyroidism","volume":"390","author":"Chaker","year":"2017","journal-title":"Lancet"},{"key":"key20200720225829_b15","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1089\/thy.2018.0257","article-title":"Association between primary hypothyroidism and nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"28","author":"Mantovani","year":"2018","journal-title":"Thyroid"},{"key":"key20200720225829_b16","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.dld.2018.08.012","article-title":"Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis","volume":"50","author":"Guo","year":"2018","journal-title":"Dig Liver Dis"},{"key":"key20200720225829_b17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2017.08.014","article-title":"Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis","volume":"16","author":"Kim","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20200720225829_b18","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1210\/jc.2016-1300","article-title":"Thyroid function and the risk of nonalcoholic fatty liver disease: The rotterdam study","volume":"101","author":"Bano","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200720225829_b19","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.3748\/wjg.v20.i25.8102","article-title":"Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review","volume":"20","author":"Eshraghian","year":"2014","journal-title":"World J Gastroenterol"},{"key":"key20200720225829_b20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.cgh.2006.07.011","article-title":"Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease","volume":"5","author":"Reddy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20200720225829_b21","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/hep.22793","article-title":"Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States","volume":"49","author":"Hassan","year":"2009","journal-title":"Hepatology"},{"key":"key20200720225829_b22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.medcli.2019.03.018","article-title":"Relationship between hypothyroidism and non-alcoholic fatty liver disease in the Spanish population","volume":"154","author":"Mart\u00ednez Escud\u00e9","year":"2020","journal-title":"Med Clin (Barc)"},{"key":"key20200720225829_b23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3350\/cmh.2015.21.4.372","article-title":"Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study","volume":"21","author":"Lee","year":"2015","journal-title":"Clin Mol Hepatol"},{"key":"key20200720225829_b24","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/ijms17091575","article-title":"Molecular pathogenesis of NASH","volume":"17","author":"Caligiuri","year":"2016","journal-title":"Int J Mol Sci"},{"key":"key20200720225829_b25","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jhep.2016.07.033","article-title":"NAFLD and liver transplantation: Current burden and expected challenges","volume":"65","author":"Pais","year":"2016","journal-title":"J Hepatol"},{"key":"key20200720225829_b26","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.3748\/wjg.v23.i36.6571","article-title":"Nonalcoholic fatty liver disease: Evolving paradigms","volume":"23","author":"Lonardo","year":"2017","journal-title":"World J Gastroenterol"},{"key":"key20200720225829_b27","first-page":"41","article-title":"Hypothyroidism and nonalcoholic fatty liver disease - a chance association?","author":"Lugari","year":"2018","journal-title":"Horm Mol Biol Clin Investig"},{"key":"key20200720225829_b28","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"key20200720225829_b29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jhep.2012.02.027","article-title":"Non-alcoholic fatty liver disease across the spectrum of hypothyroidism","volume":"57","author":"Chung","year":"2012","journal-title":"J Hepatol"},{"key":"key20200720225829_b30","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"key20200720225829_b31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1381\/096089204323013514","article-title":"Improvement of hypothyroidism after laparoscopic Roux-en-Y gastric bypass for morbid obesity","volume":"14","author":"Raftopoulos","year":"2004","journal-title":"Obes Surg"},{"key":"key20200720225829_b32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1210\/jc.2015-3444","article-title":"Body mass index and risk of nonalcoholic fatty liver disease: Two electronic health record prospective studies","volume":"101","author":"Bonato","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200720225829_b33","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/JOE-12-0542","article-title":"Non-classic thyroid hormone signalling involved in hepatic lipid metabolism","volume":"216","author":"Cordeiro","year":"2013","journal-title":"J Endocrinol"},{"key":"key20200720225829_b34","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00125-012-2598-x","article-title":"Adiponectin: mechanistic insights and clinical implications","volume":"55","author":"Turer","year":"2012","journal-title":"Diabetologia"},{"key":"key20200720225829_b35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/415339a","article-title":"Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase","volume":"415","author":"Minokoshi","year":"2002","journal-title":"Nature"},{"key":"key20200720225829_b36","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3748\/wjg.v19.i6.802","article-title":"What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?","volume":"19","author":"Finelli","year":"2013","journal-title":"World J Gastroenterol"},{"key":"key20200720225829_b37","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1111\/j.1572-0241.2005.00297.x","article-title":"Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis","volume":"100","author":"Musso","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"key20200720225829_b38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","article-title":"Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"60","author":"Polyzos","year":"2011","journal-title":"Metabolism"},{"key":"key20200720225829_b39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/JOE-11-0074","article-title":"Non-receptor-mediated actions are responsible for the lipid-lowering effects of iodothyronines in FaO rat hepatoma cells","volume":"210","author":"Grasselli","year":"2011","journal-title":"J Endocrinol"},{"key":"key20200720225829_b40","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jhep.2010.09.027","article-title":"Direct effects of iodothyronines on excess fat storage in rat hepatocytes","volume":"54","author":"Grasselli","year":"2011","journal-title":"J Hepatol"},{"key":"key20200720225829_b41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1530\/JOE-11-0288","article-title":"3,5-Diiodo-L-thyronine modulates the expression of genes of lipid metabolism in a rat model of fatty liver","volume":"212","author":"Grasselli","year":"2012","journal-title":"J Endocrinol"},{"key":"key20200720225829_b42","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3389\/fphys.2017.00706","article-title":"Both 3,5-diiodo-l-thyronine and 3,5,3\u2019-triiodo-l-thyronine prevent short-term hepatic lipid accumulation via distinct mechanisms in rats being fed a high-fat diet","volume":"8","author":"Senese","year":"2017","journal-title":"Front Physiol"},{"key":"key20200720225829_b43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"key20200720225829_b44","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.tem.2014.07.001","article-title":"Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism","volume":"25","author":"Sinha","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"key20200720225829_b45","doi-asserted-by":"crossref","first-page":"527850","DOI":"10.1155\/2010\/527850","article-title":"Skeletal muscle insulin resistance in endocrine disease","volume":"2010","author":"Peppa","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"key20200720225829_b46","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1210\/jc.2006-0478","article-title":"Insulin action in adipose tissue and muscle in hypothyroidism","volume":"91","author":"Dimitriadis","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200720225829_b47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1042\/cs1040007","article-title":"Response of glucose disposal to hyperinsulinaemia in human hypothyroidism and hyperthyroidism","volume":"104","author":"Rochon","year":"2003","journal-title":"Clin Sci (Lond)"},{"key":"key20200720225829_b48","first-page":"1206","article-title":"The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects","volume":"86","author":"Bakker","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200720225829_b49","first-page":"897","article-title":"Integrated microRNA and proteome analysis reveal a regulatory module in hepatic lipid metabolism disorders in mice with subclinical hypothyroidism","volume":"19","author":"Zhang","year":"2020","journal-title":"Exp Ther Med"},{"key":"key20200720225829_b50","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jhep.2014.06.037","article-title":"Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity","volume":"61","author":"Yan","year":"2014","journal-title":"J Hepatol"},{"key":"key20200720225829_b51","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/hep.23800","article-title":"A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate\/protein kinase A\/cyclic adenosine monophosphate-responsive element binding protein pathway","volume":"52","author":"Tian","year":"2010","journal-title":"Hepatology"},{"key":"key20200720225829_b52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mce.2017.02.015","article-title":"Thyroid stimulating hormone increases hepatic gluconeogenesis via CRTC2","volume":"446","author":"Li","year":"2017","journal-title":"Mol Cell Endocrinol"},{"key":"key20200720225829_b53","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1194\/jlr.M047654","article-title":"Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation via AMP-activated protein kinase in the liver","volume":"56","author":"Zhang","year":"2015","journal-title":"J Lipid Res"},{"key":"key20200720225829_b54","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clinbiochem.2012.03.024","article-title":"Role of mitochondria in nonalcoholic fatty liver disease--from origin to propagation","volume":"45","author":"Grattagliano","year":"2012","journal-title":"Clin Biochem"},{"key":"key20200720225829_b55","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Begriche","year":"2013","journal-title":"Hepatology"},{"key":"key20200720225829_b56","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1172\/JCI82204","article-title":"Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver","volume":"125","author":"Satapati","year":"2015","journal-title":"J Clin Invest"},{"key":"key20200720225829_b57","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s40618-020-01208-6","article-title":"The interplay between thyroid and liver: implications for clinical practice","volume":"43","author":"Piantanida","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"key20200720225829_b58","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41574-019-0218-2","article-title":"Deiodinases and their intricate role in thyroid hormone homeostasis","volume":"15","author":"Luongo","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"key20200720225829_b59","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1530\/EJE-14-0150","article-title":"Fatty liver largely explains associations of subclinical hypothyroidism with insulin resistance, metabolic syndrome, and subclinical coronary atherosclerosis","volume":"171","author":"Posadas-Romero","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"key20200720225829_b60","doi-asserted-by":"crossref","first-page":"5753039","DOI":"10.1155\/2017\/5753039","article-title":"Benefits of levothyroxine replacement therapy on nonalcoholic fatty liver disease in subclinical hypothyroidism patients","volume":"2017","author":"Liu","year":"2017","journal-title":"Int J Endocrinol"},{"key":"key20200720225829_b61","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1210\/jc.2018-00475","article-title":"Low-dose levothyroxine reduces intrahepatic lipid content in patients with type 2 diabetes mellitus and NAFLD","volume":"103","author":"Bruinstroop","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200720225829_b62","first-page":"317","article-title":"Emerging research on MGL-3196 for the treatment of nonalcoholic steatohepatitis","volume":"15","author":"Younossi","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"key20200720225829_b63","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4254\/wjh.v6.i3.114","article-title":"Thyroid hormone analogues and derivatives: Actions in fatty liver","volume":"6","author":"Coppola","year":"2014","journal-title":"World J Hepatol"},{"key":"key20200720225829_b64","doi-asserted-by":"crossref","DOI":"10.1089\/thy.2020.0071","article-title":"Thyroid hormone analogues: An update","author":"Zucchi","year":"2020","journal-title":"Thyroid"},{"key":"key20200720225829_b65","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1073\/pnas.0705286104","article-title":"The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans","volume":"105","author":"Berkenstam","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20200720225829_b66","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","article-title":"Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-\u03b2 agonist","volume":"230","author":"Taub","year":"2013","journal-title":"Atherosclerosis"},{"key":"key20200720225829_b67","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"362","author":"Ladenson","year":"2010","journal-title":"N Engl J Med"},{"key":"key20200720225829_b68","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S2213-8587(14)70006-3","article-title":"Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study","volume":"2","author":"Sjouke","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20200720225829_b69","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-017-0791-4","article-title":"Potential role of thyroid receptor \u03b2 agonists in the treatment of hyperlipidemia","volume":"77","author":"Jakobsson","year":"2017","journal-title":"Drugs"},{"key":"key20200720225829_b70","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13543784.2020.1708899","article-title":"Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196)","volume":"29","author":"Alkhouri","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"key20200720225829_b71","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"key20200720225829_b72","doi-asserted-by":"crossref","first-page":"53","DOI":"10.21037\/tgh.2019.06.06","article-title":"Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis","volume":"4","author":"Wong","year":"2019","journal-title":"Transl Gastroenterol Hepatol"},{"key":"key20200720225829_b73","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3389\/fendo.2018.00427","article-title":"3,5-diiodothyronine: A novel thyroid hormone metabolite and potent modulator of energy metabolism","volume":"9","author":"Senese","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20200720225829_b74","doi-asserted-by":"crossref","first-page":"e86890","DOI":"10.1371\/journal.pone.0086890","article-title":"The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial","volume":"9","author":"van der Valk","year":"2014","journal-title":"PLoS One"},{"key":"key20200720225829_b75","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.3390\/ijms19051535","article-title":"Metabolic reprogramming by 3-iodothyronamine (T1AM): A new perspective to reverse obesity through co-regulation of sirtuin 4 and 6 expression","volume":"19","author":"Assadi-Porter","year":"2018","journal-title":"Int J Mol Sci"},{"key":"key20200720225829_b76","doi-asserted-by":"crossref","first-page":"e13097","DOI":"10.14814\/phy2.13097","article-title":"Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine","volume":"5","author":"Selen Alpergin","year":"2017","journal-title":"Physiol Rep"},{"key":"key20200720225829_b77","doi-asserted-by":"crossref","first-page":"154203","DOI":"10.1016\/j.metabol.2020.154203","article-title":"Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis","author":"Polyzos","year":"2020","journal-title":"Metabolism"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2020.00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:19:15Z","timestamp":1783707555000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.xiahepublishing.com\/2310-8819\/ArticleFullText.aspx?sid=2&id=10.14218%2fJCTH.2020.00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,21]]},"references-count":77,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,7,21]]},"published-print":{"date-parts":[[2020,9,28]]}},"alternative-id":["10.14218\/JCTH.2020.00027"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2020.00027","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,21]]}}}